Bristol-Myers Squibb’s Opdivo® (nivolumab) has received a new indication for use with platinum-doublet chemotherapy to treat adult patients who have resectable (tumors ≥ 4cm or node positive) non-small cell lung cancer in the neoadjuvant setting.

• Recommended dosing under the new indication is 360mg of Opdivo given as an intravenous infusion with platinum-doublet chemotherapy on the same day once every three weeks for three treatment cycles.
• First FDA approved in 2014, Opdivo holds indications to treat over half a dozen forms of cancer, including multiple indications for treating non-small cell lung cancer.